MCID: SRT004
MIFTS: 51

Serotonin Syndrome

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Serotonin Syndrome

MalaCards integrated aliases for Serotonin Syndrome:

Name: Serotonin Syndrome 55 51
Malignant Carcinoid Syndrome 69
Serotonergic Syndrome 55
Serotonin Toxidrome 55
Serotonin Toxicity 55
Serotonin Storm 55

Characteristics:

Orphanet epidemiological data:

55
serotonin syndrome
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Orphanet 55 ORPHA43116
MESH via Orphanet 42 D020230
UMLS via Orphanet 70 C0699828
UMLS 69 C0024586

Summaries for Serotonin Syndrome

MalaCards based summary : Serotonin Syndrome, also known as malignant carcinoid syndrome, is related to post-traumatic stress disorder and parkinson disease, late-onset. An important gene associated with Serotonin Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Serotonergic synapse. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Serotonin syndrome (SS) is a group of symptoms that may occur following use of certain serotonergic... more...

Related Diseases for Serotonin Syndrome

Diseases related to Serotonin Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
# Related Disease Score Top Affiliating Genes
1 post-traumatic stress disorder 29.6 HTR2A MAOA MAOB SLC6A4
2 parkinson disease, late-onset 29.0 CYP2D6 HTR1A HTR2A MAOA MAOB SLC6A4
3 obsessive-compulsive disorder 28.9 CYP2D6 HTR1A HTR2A HTR3A MAOA OXT
4 anxiety 28.7 CYP2D6 CYP3A4 HTR1A HTR2A HTR3A MAOA
5 migraine with or without aura 1 28.6 CYP2D6 HTR1A HTR2A HTR3A MAOA MAOB
6 schizophrenia 5 10.6 HTR1A HTR2A
7 schizoid personality disorder 10.6 HTR1A HTR2A
8 hypoactive sexual desire disorder 10.5 HTR1A HTR2A
9 alzheimer disease 5 10.5 HTR2A SLC6A4
10 substance-induced psychosis 10.5 HTR1A HTR2A
11 rumination disorder 10.5 HTR1A HTR3A
12 social phobia 10.5 HTR3A MAOA SLC6A4
13 atypical depressive disorder 10.5 MAOA MAOB SLC6A4
14 phobic disorder 10.4 HTR1A MAOA SLC6A4
15 premature ejaculation 10.4 HTR1A HTR3A SLC6A4
16 psychosexual disorder 10.4 HTR1A HTR2A SLC6A4
17 dependent personality disorder 10.4 CYP3A4 MAOA MAOB
18 dysthymic disorder 10.4 HTR2A MAOA SLC6A4
19 agoraphobia 10.4 HTR1A MAOA SLC6A4
20 periodic limb movement disorder 10.4 HTR1A HTR2A SLC6A4
21 postpartum depression 10.4 HTR1A MAOA SLC6A4
22 paranoid schizophrenia 10.4 HTR2A MAOA SLC6A4
23 antisocial personality disorder 10.4 MAOA MAOB SLC6A4
24 adenoma of the pancreas 10.4 CHGA SST
25 paraphilia disorder 10.4 MAOA MAOB OXT
26 bipolar i disorder 10.4 HTR1A HTR2A SLC6A4
27 chronic fatigue syndrome 10.4 HTR1A MAOA SLC6A4
28 substance abuse 10.4 CYP2D6 MAOA SLC6A4
29 brunner syndrome 10.3 HTR1A HTR3A MAOA SLC6A4
30 substance dependence 10.3 CYP2D6 MAOA SLC6A4
31 hemangioma of liver 10.3 CYP3A4 IFNA2
32 early-onset schizophrenia 10.3 HTR2A HTR3A MAOA SLC6A4
33 borderline personality disorder 10.3 HTR1A HTR2A MAOA SLC6A4
34 pathological gambling 10.3 HTR2A MAOA MAOB SLC6A4
35 endogenous depression 10.3 HTR1A HTR2A MAOA SLC6A4
36 asperger syndrome 10.3 MAOB OXT SLC6A4
37 kleptomania 10.3 CYP3A4 HTR1A MAOA SLC6A4
38 autoimmune atrophic gastritis 10.3 CHGA GAST
39 postgastrectomy syndrome 10.3 PYY SST
40 dyspepsia 10.3 HTR1A HTR3A SLC6A4 SST
41 pancreatic somatostatinoma 10.3 MEN1 SST
42 glucagonoma 10.3 CHGA GHRH SST
43 motion sickness 10.3 HTR1A HTR3A TAC1
44 hormone producing pituitary cancer 10.2 MEN1 SST
45 pylorospasm 10.2 GAST SST
46 central nervous system disease 10.2 CYP2D6 HTR2A MAOB SLC6A4
47 gastroparesis 10.2 CYP2D6 GAST HTR3A
48 autism spectrum disorder 10.2 HTR2A MAOA OXT SLC6A4
49 generalized anxiety disorder 10.2 HTR1A HTR2A HTR3A MAOA SLC6A4
50 personality disorder 10.2 HTR1A HTR2A MAOA MAOB SLC6A4

Comorbidity relations with Serotonin Syndrome via Phenotypic Disease Network (PDN):


Intestinal Obstruction

Graphical network of the top 20 diseases related to Serotonin Syndrome:



Diseases related to Serotonin Syndrome

Symptoms & Phenotypes for Serotonin Syndrome

GenomeRNAi Phenotypes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Serotonin Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 HTR1A HTR2A HTR3A MAOA MAOB OXT
2 endocrine/exocrine gland MP:0005379 9.81 CHGA GAST GHRH HTR2A HTR3A MEN1
3 homeostasis/metabolism MP:0005376 9.8 CHGA GAST GHRH HTR1A HTR3A MAOA
4 nervous system MP:0003631 9.4 NOTCH1 OXT PYY SLC6A4 SST SSTR1

Drugs & Therapeutics for Serotonin Syndrome

Drugs for Serotonin Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 2,Phase 1
3
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
6
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
7
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
8
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 6400441 383414
9
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
10
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
11 lanreotide Approved Phase 3,Phase 2 108736-35-2
12
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
13
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Hormone Antagonists Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
17 Hormones Phase 3,Phase 2,Phase 1
18 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 2, Phase 3, Phase 1
22 Antimetabolites Phase 2, Phase 3,Phase 1
23 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
24 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
25 Angiopeptin Phase 3,Phase 2
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Pharmaceutical Solutions Phase 3,Phase 2
28 Antifungal Agents Phase 3,Phase 2,Phase 1
29 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
31 Folate Nutraceutical Phase 2, Phase 3
32 Vitamin B9 Nutraceutical Phase 2, Phase 3
33
Hydroxyurea Approved Phase 2 127-07-1 3657
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
36
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
37
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
39
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
40
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
41
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
42
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
43
Floxuridine Approved Phase 2 50-91-9 5790
44
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
45
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
46
Pancrelipase Approved, Investigational Phase 2 53608-75-6
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Palonosetron Approved, Investigational Phase 2 135729-61-2, 135729-56-5, 119904-90-4 148211
49
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
50
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938

Interventional clinical trials:

(show top 50) (show all 65)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
4 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
5 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
6 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
7 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
8 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
9 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
10 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
11 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start);4-Week LX1606 Open Label Dose Extension;72-Week LX1606 Open Label Dose Extension
12 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Low Dose LX1606 Part 1;Mid-Low Dose LX1606 Part 1;Mid-High Dose LX1606 Part 1;High Dose LX1606 Part 1;Part 2 LX1606 Expanded Cohort;Placebo;LX1606 Open Label Dose Extension;LX1606 Open Label Extension 2;LX1606 Open Label Extension 3
13 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
14 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
15 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
16 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
17 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
18 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
19 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
20 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
21 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
22 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
23 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
24 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
25 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
26 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
27 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
28 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
29 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
30 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Recruiting NCT01782443 Phase 2 Ziv-aflibercept
31 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
32 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Active, not recruiting NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
33 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
34 Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
35 Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
36 P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
37 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
38 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
39 Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
40 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
41 An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
42 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
43 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
44 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
45 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
46 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
47 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
48 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
49 Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
50 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1

Search NIH Clinical Center for Serotonin Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Serotonin Syndrome

Anatomical Context for Serotonin Syndrome

MalaCards organs/tissues related to Serotonin Syndrome:

38
Liver, Bone, Breast, Lung, Testes, Endothelial, Brain

Publications for Serotonin Syndrome

Articles related to Serotonin Syndrome:

(show top 50) (show all 607)
# Title Authors Year
1
Serotonin syndrome during a heat wave. ( 29437313 )
2018
2
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication. ( 29317102 )
2018
3
Severe Serotonin Syndrome in an Autistic New Psychoactive Substance User After Consumption of Pills Containing Methoxphenidine and I+-Methyltryptamine. ( 29210865 )
2018
4
Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. ( 29210063 )
2018
5
Comment on "Probable Tapentadol-Associated Serotonin Syndrome After Overdose". ( 28515500 )
2017
6
Famotidine-induced reversal of meperidine-related serotonin syndrome: a case report. ( 28367296 )
2017
7
Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. ( 28784915 )
2017
8
In Reply: Serotonin syndrome. ( 28530903 )
2017
9
Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. ( 28796019 )
2017
10
Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome. ( 29134498 )
2017
11
Cervical Spinal Cord Stimulation with Concomitant Serotonin Norepinephrine Reuptake Inhibitor Therapy Leading to the Serotonin Syndrome. ( 28057811 )
2017
12
Controversies in Serotonin Syndrome Diagnosis and Management: A Review. ( 29207768 )
2017
13
Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome. ( 28839121 )
2017
14
Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report. ( 28622210 )
2017
15
Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. ( 28975823 )
2017
16
To the Editor: Serotonin syndrome. ( 28530902 )
2017
17
Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: A Retrospective Study Utilizing Two Large US Claims Databases. ( 29286588 )
2017
18
Serotonin syndrome in patients with headache disorders. ( 28784913 )
2017
19
Metoclopramide-induced Serotonin Syndrome. ( 28321081 )
2017
20
Comment on Tapentadol and Serotonin Syndrome. ( 28515499 )
2017
21
Serotonin Syndrome in a Pediatric Patient After Vilazodone Ingestion. ( 28350718 )
2017
22
Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis. ( 28943544 )
2017
23
Serotonergic medications, herbal supplements, and perioperative serotonin syndrome. ( 28667541 )
2017
24
Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever. ( 28210931 )
2017
25
Serotonin syndrome due to co-administration of linezolid and methadone. ( 28956544 )
2017
26
Fatal serotonin syndrome in a patient with Marchiafava-Bignami disease: Combined neurological and psychiatric emergency. ( 29169770 )
2017
27
Methylene blue-induced serotonin syndrome after left ventricular assist device implantation: A case report and literature review. ( 28655448 )
2017
28
Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research. ( 29336654 )
2017
29
Staying Topical: An Unusual Case of Serotonin Syndrome. ( 28806389 )
2017
30
Rare case of severe serotonin syndrome leading to bilateral compartment syndrome. ( 28258180 )
2017
31
Codeine Precipitating Serotonin Syndrome in a Patient in Therapy with Antidepressant and Triptan. ( 28783942 )
2017
32
A review of vilazodone exposures with focus on serotonin syndrome effects. ( 28594246 )
2017
33
Serotonin Syndrome Following an Uncomplicated Orthopedic Surgery in a Patient With Post-Traumatic Stress Disorder. ( 27612381 )
2016
34
Cyproheptadine-dependent chronic serotonin syndrome. ( 27841211 )
2016
35
No laughing matter: nitrous oxide triggers serotonin syndrome in an anxious adolescent. ( 27290939 )
2016
36
Serotonin Syndrome With Fluoxetine: Two Case Reports. ( 27999518 )
2016
37
New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain. ( 27192423 )
2016
38
Serotonin Syndrome Following Methylene Blue Administration for Vasoplegic Syndrome. ( 26934199 )
2016
39
Methylene Blue Causing Serotonin Syndrome Following Cystocele Repair. ( 27617215 )
2016
40
Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. ( 27433163 )
2016
41
Linezolid and Rasagiline - A culprit for serotonin syndrome. ( 26997732 )
2016
42
Serotonin syndrome: Preventing, recognizing, and treating it. ( 27824534 )
2016
43
Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. ( 27406219 )
2016
44
Serotonin syndrome presenting as surgical emergency: A report of two cases. ( 27076715 )
2016
45
A Case Report of Probable Paliperidone ER-Induced Serotonin Syndrome in a 17-Year-Old Taiwanese Female With New Onset Psychosis. ( 26945397 )
2016
46
Serotonin Syndrome: Prophylactic Treatment With Cyproheptadine. ( 27828700 )
2016
47
Ocular Flutter in the Serotonin Syndrome. ( 27806222 )
2016
48
Electroconvulsive Therapy Induces Transient Sensitivity for a Serotonin Syndrome: A Case Report. ( 27458743 )
2016
49
Management of Serotonin Syndrome and Neuroleptic Malignant Syndrome. ( 27469512 )
2016
50
Probable Serotonin Syndrome and Withdrawal Symptoms Caused by Milnacipran. ( 27904101 )
2016

Variations for Serotonin Syndrome

Expression for Serotonin Syndrome

Search GEO for disease gene expression data for Serotonin Syndrome.

Pathways for Serotonin Syndrome

Pathways related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 GHRH HTR1A HTR2A OXT PYY SST
2 11.55 CYP2D6 HTR1A HTR2A HTR3A MAOA MAOB
3 11.44 HTR1A HTR2A HTR3A MAOA SLC6A4 SST
4
Show member pathways
11.33 CYP2D6 CYP3A4 SLC6A4
5 11 HTR1A HTR2A HTR3A MAOA SLC6A4
6
Show member pathways
10.61 MAOA MAOB
7 10.51 MAOA MAOB
8
Show member pathways
10.44 MAOA MAOB

GO Terms for Serotonin Syndrome

Cellular components related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CHGA GAST GHRH IFNA2 OXT PYY
2 extracellular region GO:0005576 9.32 CGB3 CHGA GAST GHRH IFNA2 NOTCH1

Biological processes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.89 HTR2A HTR3A SST TAC1
2 G-protein coupled receptor signaling pathway GO:0007186 9.81 GAST GHRH HTR1A HTR2A OXT PYY
3 neuropeptide signaling pathway GO:0007218 9.8 PYY SSTR1 TAC1
4 response to nutrient GO:0007584 9.77 SLC6A4 SST SSTR1
5 memory GO:0007613 9.72 HTR2A OXT SLC6A4
6 digestion GO:0007586 9.71 PYY SST SSTR1
7 vasoconstriction GO:0042310 9.63 HTR1A SLC6A4
8 negative regulation of cell-substrate adhesion GO:0010812 9.62 MEN1 NOTCH1
9 positive regulation of ossification GO:0045778 9.62 OXT TAC1
10 positive regulation of renal sodium excretion GO:0035815 9.61 OXT TAC1
11 behavior GO:0007610 9.61 HTR1A HTR2A
12 sleep GO:0030431 9.58 HTR2A OXT
13 neurotransmitter catabolic process GO:0042135 9.58 MAOA MAOB
14 regulation of behavior GO:0050795 9.57 HTR1A HTR2A
15 oxidative demethylation GO:0070989 9.56 CYP2D6 CYP3A4
16 response to steroid hormone GO:0048545 9.54 MAOB OXT SST
17 dopamine catabolic process GO:0042420 9.52 MAOA MAOB
18 heterocycle metabolic process GO:0046483 9.51 CYP2D6 CYP3A4
19 regulation of receptor activity GO:0010469 9.5 CGB3 GAST GHRH IFNA2 OXT PYY
20 sperm ejaculation GO:0042713 9.49 OXT SLC6A4
21 regulation of hormone secretion GO:0046883 9.48 HTR1A HTR2A
22 drug catabolic process GO:0042737 9.46 CYP2D6 CYP3A4
23 monoterpenoid metabolic process GO:0016098 9.43 CYP2D6 CYP3A4
24 response to food GO:0032094 9.43 GAST GHRH OXT
25 serotonin receptor signaling pathway GO:0007210 9.4 HTR1A HTR2A
26 alkaloid catabolic process GO:0009822 9.32 CYP2D6 CYP3A4
27 cell-cell signaling GO:0007267 9.17 CGB3 GHRH IFNA2 PYY SST SSTR1

Molecular functions related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 primary amine oxidase activity GO:0008131 9.16 MAOA MAOB
2 serotonin binding GO:0051378 9.13 HTR1A HTR2A HTR3A
3 hormone activity GO:0005179 9.02 CGB3 GAST OXT PYY SST

Sources for Serotonin Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....